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Conserved regulation of RNA processing in
somatic cell reprogramming
Alexander Kanitz1,2†, Afzal Pasha Syed1,2†, Keisuke Kaji3 and Mihaela Zavolan1,2*
Abstract
Background: Along with the reorganization of epigenetic and transcriptional networks, somatic cell
reprogramming brings about numerous changes at the level of RNA processing. These include the expression of
specific transcript isoforms and 3’ untranslated regions. A number of studies have uncovered RNA processing
factors that modulate the efficiency of the reprogramming process. However, a comprehensive evaluation of the
involvement of RNA processing factors in the reprogramming of somatic mammalian cells is lacking.
Results: Here, we used data from a large number of studies carried out in three mammalian species, mouse,
chimpanzee and human, to uncover consistent changes in gene expression upon reprogramming of somatic cells.
We found that a core set of nine splicing factors have consistent changes across the majority of data sets in all
three species. Most striking among these are ESRP1 and ESRP2, which accelerate and enhance the efficiency of
somatic cell reprogramming by promoting isoform expression changes associated with mesenchymal-to-epithelial
transition. We further identify genes and processes in which splicing changes are observed in both human and
mouse.
Conclusions: Our results provide a general resource for gene expression and splicing changes that take place
during somatic cell reprogramming. Furthermore, they support the concept that splicing factors with evolutionarily
conserved, cell type-specific expression can modulate the efficiency of the process by reinforcing intermediate
states resembling the cell types in which these factors are normally expressed.
Keywords: iPS cells, Somatic cell reprogramming, RNA processing, Alternative splicing
Background
Integrated analyses of genomics, epigenomics, tran-
scriptomics, and proteomics data are systematically un-
ravelling the gene regulatory networks underlying the
reprogramming of differentiated cells into induced pluri-
potent stem cells (iPSCs) [1–7], particularly the under-
lying ‘epigenetic landscape’ [8]. These studies have
improved our understanding of the dynamics of cell
state transitions and of cell fate decisions, while the vast
number of resulting data sets have enabled the develop-
ment of computational models for predicting regulatory
switches, as well as to facilitate cellular reprogramming
and transdifferentiation [9, 10].
The ‘molecular roadmap’ of somatic cell reprogram-
ming includes bursts of changes in mRNA, miRNA and
histone modification levels during the first three days
and at the end of reprogramming. Between these bursts
is a less understood period of relatively little transcrip-
tional change. The initial phase resembles a
mesenchymal-epithelial transition (MET) [11], a process
that takes place during the development of various or-
gans as well as during cancer transformation. Many in-
teractions that have been uncovered in the context of
MET or its reversal, epithelial-mesenchymal transition
(EMT), are also studied in the context of reprogram-
ming [12]. Interestingly, some of the important changes
occur at the level of RNA processing through alternative
splicing. For example, the inclusion of 10 variable exons
in messages of the adhesion molecule Cd44, which is
important for MET [13], is driven by ESRP1 and ESRP2
(epithelial splicing regulatory protein 1 and 2) [14].
ESRP1 has recently been reported to also enhance
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somatic cell reprogramming [15, 16], partly through the
alternative splicing of the Grhl1 (grainyhead like transcrip-
tion factor 1) [15]. Although evidence of deeply conserved
regulators of pluripotency has started to emerge [17], a
mammalian pluripotency network that includes splicing
regulators has not been reconstructed so far.
Aiming to identify conserved regulators of somatic cell
reprogramming we have analyzed mRNA sequencing
data obtained in 14 reprogramming studies that were
carried out in mouse, chimpanzee and human. We
found that functional categories related to ‘RNA pro-
cessing’ and ‘mRNA splicing’ were strongly
over-represented among genes whose expression was
higher in iPSCs compared to parental cells, in line with
general changes in cell physiology that were reported
previously [18–20]. Furthermore, we identified a set of 9
splicing-related genes, which exhibited a highly consist-
ent pattern of expression in iPSCs and parental cells
across all species and types of reprogramming methods.
Among these, ESRP1 showed the strongest and most
conserved increase in expression in iPSCs compared to
parental cells. While the potentiating effect of ESRP1 on
reprogramming efficiency had already been reported
[15], here we demonstrate that ectopic expression of ei-
ther Esrp paralog accelerates the reprogramming kinetics
and increases reprogramming efficiency. Finally, we
found that transcripts related to the cytoskeleton, cell
adhesion and epigenetic regulation undergo splicing/iso-
form changes in both human and mouse systems. Our
analysis supports the concept that splicing factors with
an evolutionarily-conserved cell-type-specificity of ex-
pression enforce the identity of the corresponding cell
types and can modulate reprogramming efficiency.
Results
Expression analysis of somatic cell reprogramming
systems across species
One of the first reprogramming studies that employed
deep sequencing, investigated somatic copy number mo-
saicism in 21 iPSC lines derived from the skin fibroblasts
of 7 donors [21]. Comparing gene expression of induced
pluripotent stem cells (iPSCs) with that of parental fibro-
blasts in this extensive data set, we found that RNA
binding, processing and splicing-related factors were
strongly enriched among genes whose expression is in-
creased in iPSCs (Additional file 1). To evaluate the gen-
erality of this observation, we have queried the NCBI
Sequence Read Archive [22] and identified 14 studies of
primate (human, chimpanzee) and rodent (mouse) som-
atic cell reprogramming (Table 1) that generated deep
sequencing data and had replicate samples for both par-
ental cells and reprogramming endpoints (see Methods
for details). These studies covered a variety of cell types
and reprogramming methods and resulted in a total of
376 Illumina RNA-Seq libraries (Additional file 2; 140
starting and 184 end points as well as 52 intermediate
samples, with 4 to 138 samples per study) of varying se-
quencing depths (Additional file 3: Figure S1A) and read
lengths (Additional file 3: Figure S1B).
Principal component analysis of gene expression levels
revealed the expected clustering of samples from similar
cell types in all organisms (Fig. 1a, b, c). The first princi-






of the variance, de-
pending on the species, and clearly separated fibroblasts
from iPSCs. Murine adipose progenitor cells (APC) clus-
tered together with fibroblasts, possibly due to their
Table 1 Publicly available RNA-Seq data sets analyzed in this study
Id Accession Organism Cell types Reference
A SRP011318 Mouse Adipose progenitor cells, fibroblasts, hematopoietic progenitor cells, iPSCs [95]
B SRP016568 Human Fibroblasts, iPSCs [21]
C SRP026281 Mouse Fibroblasts, iPSCs (chemical) [96]
D SRP033561 Mouse Fibroblasts, iPSCs [97]
E SRP033569 Human Fibroblasts, iPSCs (retrovirus), iPSCs (Sendai virus) [98]
F SRP033700 Mouse Fibroblasts, iPSCs [99]
G SRP045688 Mouse Fibroblasts, iPSCs [100]
H SRP045999 Chimpanzee, Human Fibroblasts, iPSCs, lymphoblastoids (human only) [101]
I SRP049340 Human hiF, hiF-T, iPSCs [28]
J SRP052014 Mouse iPSCs, spermatogonial stem cells [102]
K SRP056571 Mouse Fibroblasts, iPSCs [103]
L SRP059670 Mouse Fibroblasts, iPSCs [15]
M SRP063867 Human Fibroblasts, iPSCs [104]
N SRP064357 Mouse Fibroblasts, iPSCs (chemical) [105]
The columns indicate NCBI Sequence Read Archive (SRA) accession numbers, the organism or organisms and cell types from which samples were prepared, and a
reference to the study for which the data was originally generated
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similarity and the fact that protocols to separate these
cell types have only recently been established [23]. Hu-
man lymphoblastoid (LB) cells, mouse hematopoietic
progenitor (HPC) and mouse spermatogonial stem cells
(SSC) were located in between fibroblasts and iPSCs in
the coordinate system of the first principal component.
Thus, batch effects did not mask the relationship be-
tween samples, with only the fibroblasts and iPSCs from
study SRP033561 being somewhat separated from the
bulk of the corresponding cell lines from all other mouse
studies along the second principal component (explain-
ing ~9% of the variation). This may be related to the
A B C
D E
Fig. 1 Analysis of gene expression. Principal component analysis of gene expression inferred from human (a), mouse (b) and chimpanzee (c)
RNA-Seq libraries. x and y axes correspond to the first and second principal components. Axis labels indicate the amount of variance explained.
Colors correspond to cell types (see below for abbreviations), while symbols indicate the individual studies from which the data sets were
derived (see also Table 1). (d and e) Gene set enrichment analyses of genes that were differential gene expression in reprogrammed cells relative
to their parental somatic cells. The significance (log10 false discovery rates (FDR) of enrichments in either differentially expressed genes (d) or in
genes with increased expression (“upregulated”) during iPSC formation (e) relative to all expressed genes are shown as heatmaps. GO terms are
shown in rows and specific comparisons (data sets) are shown in columns. The organisms from which individual data sets were derived are
indicated by the color in the bar above the heatmaps: human - blue; mouse - red; chimpanzee - purple. For clarity, values of log10 FDR were
capped at -50. Column dendrograms are based on complete linkage clustering with Euclidean distances. Column (x axis) labels indicate the data
sets that were compared, using a 1-letter code that maps to the corresponding Sequence Read Archive accession (see legend above (d) and (e),
right side). Abbreviations are: APC, adipose progenitor cells; ciPSC, chemically induced pluripotent stem cells; FB, fibroblasts; iPSC, induced
pluripotent stem cells; hiF, human inducible fibroblast-like cells; HPC, hematopoietic progenitor cells; LB, lymphoblastoid cells; MEF, mouse
embryonic fibroblasts; SSC, spermatogonial stem cells. hiF-T cells constitutively express human TERT (telomerase reverse transcriptase). See Table
1, Table S2 and the original references for details on specific studies
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lower mapping rate of reads obtained in the study (Add-
itional file 3: Figure S1C/D).
Analysis of gene expression changes in the 20
iPSC-cell of origin comparisons (Table 1, Additional file
4) showed that RNA-binding proteins, RNA processing
and splicing factors are enriched among the genes that
are upregulated in the iPSCs from all three species (Fig.
1d, e, Additional file 5: Figure S2). Their enrichment was
detectable but less pronounced among genes that were
differentially expressed. This systematic tendency for
higher expression in iPSCs is striking, because genes as-
sociated with gene ontology terms “RNA splicing” (Add-
itional file 5: Figure S2A/B) and “RNA processing”
(Additional file 5: Figure S2C/D) underwent, in fact,
smaller changes in expression compared to genes not in
these functional categories, as evidenced by shifts of the
density functions of log2 fold changes and cumulative
distribution functions of absolute log2 fold changes in
the expression of genes associated with these terms
compared to control genes. Specifically, only ~5% of
these genes had absolute log2 fold changes larger than 2
between iPSCs and fibroblasts compared to ~25% of
genes from other functional categories, regardless of the
study, the protocol used for preparing the samples and
the organism from which the cells were derived. Genes
in the more general functional category of “gene regula-
tion” did not share the low magnitude of change or the
bias towards upregulation (Additional file 5: Figure S2E/
F), while genes associated with GO terms “spliceosomal
complex” and “ribosome” did (Fig. 2g, h, i and j), indicat-
ing a more general change in cell physiology, as reported
earlier [18–20].
Evolutionarily conserved patterns of splicing factor
expression in somatic cell reprogramming
We then sought to identify splicing factors with consistent
expression changes across studies and species and found
that 26 splicing factors exhibited robust and relatively
large (median fold change ≥ 5 in studies of at least one
species) expression changes (Fig. 2a), 19 having increased
and 6 decreased expression in iPSCs compared to fibro-
blasts. Around a third of splicing-associated genes (9 out
of 26) had a median fold change ≥ 5 in all three organisms:
AHNAK (AHNAK nucleoprotein; also known as des-
moyokin), CELF5 (CUGBP Elav-like family member 5),
ESRP1, LGALS3 (galectin 3), MBNL1/2 (muscleblind like
splicing regulator 1 and 2), RBM47 (RNA binding motif
protein 47), SNRPN (small nuclear ribonucleoprotein
polypeptide N), ZCCHC24 (zinc finger CCHC-type con-
taining 24). Another six met the expression change cutoff
in human and mouse: ELAVL2 (ELAV like RNA binding
protein 2), RBFOX3 (RNA binding fox-1 homolog 3),
ESRP2 (epithelial splicing regulatory protein 2), PSIP1
(PC4 and SFRS1 interacting protein 1), USP49 (ubiquitin
specific peptidase 49), SRSF12 (serine and arginine rich
splicing factor 12). This is considerably more than would
be expected if expression changes were randomized over
genes within individual species (Fig. 2b; P value for the
overlap across all species <10-22; P values for pairwise
comparisons ranging from ~10-10 to ~10-19). Only one
gene, AFF2 (AF4/FMR2 family member 2, a gene associ-
ated with fragile X-linked mental retardation) increased in
expression during the reprogramming of primate cells,
but decreased during mouse cell reprogramming. The
core set of 9 highly conserved splicing factors included
genes coding for recently described regulators of repro-
gramming such as MBNL1/2 [23], ESRP1, RBM47 and
ZCCHC24 [15]. RBFOX2 (RNA binding fox-1 homolog
2), SON (SON DNA binding protein), SRSF2/3/11 (serine
and arginine rich splicing factor 2, 3 and 11) and U2AF1
(U2 small nuclear RNA auxiliary factor 1), other splicing
factors that have been experimentally linked to the effi-
ciency of reprogramming [24–27], showed considerably
less pronounced changes in their mRNA levels in the sys-
tems that we analyzed (Fig. 2).
In all species, the gene with the largest and most con-
sistent increase in expression in iPSCs compared to par-
ental cells was ESRP1 (Fig. 2a). In contrast, its ESRP2
paralog underwent a similarly large expression change in
primate iPSCs, but less pronounced in mouse iPSCs.
Time series mRNA sequencing data from human and
mouse reprogramming that are also available [15, 28]
helped explain this discrepancy. Specifically, we found
that while expression of both ESRP paralogs steadily and
concurrently increased during the reprogramming of hu-
man cells (Additional file 6: Figure S3), in mouse cell re-
programming this pattern was shared by Esrp1, but not
by Esrp2. Rather, the expression of Esrp2 increased only
transiently during the reprogramming of mouse cells
(Additional file 7: Figure S4). Of note, DDX25, ELAV2,
and, to a lesser extent, CELF5 and USP49, exhibited an
expression pattern similar to that of ESRP2, with their
expression strongly increasing towards the final stage of
reprogramming in human, but decreasing in mouse re-
programming systems (Additional file 6: Figure S3/ Add-
itional file 7: Figure S4). RBFOX3, a neuronal marker,
and RBM11 showed a similar increase in expression in
human reprogramming systems, but their transcripts
were almost entirely absent from mouse cells along the
entire reprogramming timeline (sum of TPM <1; Add-
itional file 6: Figure S3/ Additional file 7: Figure S4).
Splicing factors whose expression decreased upon repro-
gramming included MBNL1/2, whose siRNA-mediated
knock-down was found to increase reprogramming effi-
ciency [23]. Down-regulated genes further encode the ca-
nonical splicing factor CELF2, the zinc finger-containing
protein ZCCHC24, the neuroblast differentiation-associated
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scaffolding protein AHNAK that was recently found to bind
RNAs [29], and the carbohydrate-binding protein LGALS3
that also functions in splicing [30]. Interestingly, whereas
these factors are expressed at high levels across a panel of
human tissues [31], the splicing factors whose expression in-
creases upon reprogramming often have a more restricted
pattern of expression across human cell types (Fig. 2c). Fur-
thermore, genes whose expression increased most upon re-
programming of primate somatic cells appear to also
undergo large expression changes in a large number of can-
cers (Additional file 8: Figure S5). While RBFOX3, RBM11
(RNA binding motif protein 11) and DDX25 (DEAD-box
helicase 25) are generally downregulated in cancers com-
pared to normal cells, the dysregulation of CELF5, ELAVL2
and ESRP1 is dependant on the type of cancer. In particular,
ESRP1 expression is heavily upregulated in (endo)cervical
cancers (~192-fold), but strongly downregulated (~136-fold)
in sarcomas.
When considering genes annotated with the more gen-
eral “RNA processing” gene ontology term, we identified
a total of 53 genes with large and consistent expression
changes (median fold change ≥5 across the comparisons
of one or more species) between iPSCs and parental cells
(Additional file 9: Figure S6A). Similarly to splicing fac-
tors, this is much more than expected by chance (Add-
itional file 9: Figure S6B). Beyond the already discussed
splicing factors, 9 additional ‘RNA processing’ genes
emerged from this analysis, in all three species: ATXN1
(ataxin 1), EGFR (epidermal growth factor receptor),
NR2F1 (nuclear receptor subfamily 2 group F member
1), and TGFB1 (transforming growth factor beta 1) had
lower expression, while CHD7 (chromodomain helicase
DNA binding protein 7), LIN28A/B (lin-28 homolog A
and B), MDN1 (midasin AAA ATPase 1), and TRIM71
(tripartite motif containing 71) had higher expression in
pluripotent compared to somatic cells. In particular, the
LIN28A protein has been demonstrated to play import-
ant roles in reprogramming from very early on, being
able to substitute for c-Myc in the “Yamanaka cocktail”
[32]. Recently, similar observations have been reported
for the LIN28B paralog [33]. Interesting, although these
genes are annotated as genes involved in ‘RNA process-
ing’, they are better for other functions, such as DNA or
chromatin binding.
Overexpression of ESRPs enhances the reprogramming of
mouse embryonic fibroblasts
We were intrigued by the discordant expression pattern of
the ESRP2 paralog in human and mouse reprogramming
systems and wondered whether in spite of its transient in-
duction during the reprogramming of mouse cells, this
protein can nevertheless increase reprogramming effi-
ciency, as does its paralog. To answer this question we
used a previously described reprogramming system of
mouse embryonic fibroblasts (MEF) that can be induced
to express the set of “MKOS” transcription factors (Myc,
myelocytomatosis oncogene; Klf4, Kruppel-like factor 4
(gut); Oct4/Pou5f1, POU domain, class 5, transcription
factor 1; Sox2, SRY (sex determining region Y)-box 2)
from a genomically-integrated construct. Application of
doxycycline to these transgenic MEFs (TNG-MKOS--
MEFs) induced the expression of the MKOS factors as
well as of mOrange. This allowed the monitoring of
MKOS expression during the reprogramming process,
while the endogenous Nanog-GFP [34] reporter enabled
the detection and quantification of pluripotent stem cell
colonies 15 days after MKOS induction.
Transduction of TNG-MKOS-MEFs with retroviruses
expressing either Esrp1 or Esrp2 (Additional file 10: Figure
S7A) followed by induction with doxycycline resulted in
1.6 and 1.9 fold more Nanog-GFP positive colonies, re-
spectively, relative to Renilla luciferase-transduced or to
non-transduced controls (Fig. 3a, and b). Expression of
pluripotency markers and their differentiation capacity
was confirmed by qRT-PCR, spontaneous differentiation
and neuronal lineage differentiation (Additional file 10:
Figure S7B-F). Thus, although Esrp2’s induction during
transcription factor-induced reprogramming of mouse
(See figure on previous page.)
Fig. 2 Splicing factors with consistent gene expression changes. (a) The left heatmap shows log2 fold-changes in reprogrammed versus parental
cells (columns) for genes (rows; human gene symbol) associated with GO term “RNA splicing” (GO:0008380 or descendants). Orange, blue and
white indicate higher, lower, or unchanged expression, respectively, in the reprogrammed state. Only genes with (i) a median expression of at
least 4 TPM in either endpoint and (ii) a 5-fold difference in expression in at least half of the comparisons of any organism (human, chimpanzee,
mouse) are shown. Genes for which one-to-one pairwise orthologous relationships and corresponding gene symbols were unavailable (Ensembl
release 84) were disregarded. Putative splicing factors previously implicated in reprogramming (symbols in maroon) [15, 23–27, 66] were included,
regardless of them passing the stated criteria. Some of these were not associated with GO:0008380 or descendants(#) and/or required manual
curation of orthologous relationships(†). The right heatmap shows an additional summary: the median fold change for each organism (black
borders indicate genes that pass the expression and fold change filters in a given organism). Organism color coding, column labels and
dendrograms/clustering as in Fig. 1d/e. See Table 1 and Additional file 2 for details on the used data. (b) Evaluation of the significance of
overlaps of genes identified in sets of organisms done with the SuperExactTest R package [93]. Fold enrichments and corresponding P values are
indicated for all 2-way, as well as for the 3-way comparison. (c) Expression levels of genes in (A) in a panel of human tissues in The Human
Protein Atlas (release 16) [31] (log2 TPM) shown along with the median fold-change observed between iPSCs and parental cells in samples from
the three organisms (taken from panel A). Dendrograms and clustering as in Fig. 1d/e





Fig. 3 (See legend on next page.)
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cells is only transient (Additional file 7: Figure S4), it ap-
pears to increase reprogramming efficiency to a similar
degree as its stably induced Esrp1 paralog.
ESRPs enhance MET and accelerate the reprogramming of
TNG-MKOS-MEFs
As ESRPs are important for EMT [14] and as the con-
verse MET is an essential stage in MEF reprogramming
[35], we investigated the kinetics of the reprogramming
process upon expression of either Esrp paralog, by moni-
toring levels of the CD44 and ICAM1 cell surface
markers [36]. During reprogramming, mouse fibroblasts
convert from CD44+ / ICAM1- to CD44- / ICAM1- and
then to CD44- / ICAM1+ cells, the latter population
containing a substantial fraction of pluripotent cells.
Flow cytometry-based analysis 5 days after doxycycline
induction revealed that the proportion of CD44- /
ICAM1- cells was 2-fold higher in Esrp1/2-transduced
compared to Renilla luciferase-transduced
TNG-MKOS-MEFs. We also observed a similar trend 2
days after doxycycline induction, but the data is some-
what noisy, likely due to variation in the onset of trans-
gene expression following retroviral transduction. Taken
together, these data indicate that both ESRPs accelerate
the reprogramming of MEFs (Fig. 3c, d). To further de-
termine whether an accelerated MET underlies the ac-
celerated reprogramming, we measured the expression
of epithelial marker Cdh1 (cadherin 1; E-cadherin) [37]
by qRT-PCR. Indeed, we found that Esrp1/2-transduced
cells expressed 2-fold higher levels of Cdh1 at day 2 and
3.5-7-fold higher levels at day 5, compared to
non-transduced cells (Fig. 3e). The difference in the im-
pact of Esrp2 and Esrp1 overexpression on Cdh1 levels
at day 5 is consistent with a previous study demonstrat-
ing that the knockdown of Esrp paralogs has different ef-
fects on Cdh1 expression in the context of cancer cell
motility [38]. Conversely, the expression of the mesen-
chymal marker Cdh2 (cadherin 2; N-cadherin) was 1.5
fold lower at day 2 and ~2-fold lower at day 5 in ESRP1/
2-transduced compared to non-transduced cells (Fig.
3f ).
Cd44 isoform switching parallels ESRP-induced
acceleration of reprogramming
The key role of ESRPs in EMT is partly due to them
promoting the inclusion of variant exons 6-15 in Cd44
transcripts, leading to a switch from the ‘standard’
(“Cd44s”) isoform to epithelial (“Cd44v”) isoforms [39]
(Fig. 4a). As mentioned above, Cd44 gene expression is
down-regulated during reprogramming, both at the
protein [36] and at the mRNA level (Fig. 4b, and c).
In addition, using equal amounts of Cd44 cDNA as
starting material, we found by semi-quantitative
RT-PCR that the relative abundance of Cd44v iso-
forms was higher in cells transduced with Esrp1/2
(Fig. 4d) compared to non-transduced cells. These re-
sults demonstrate that similar to ESRP1, ESRP2 in-
creases the efficiency of somatic cell reprogramming
in mouse, accelerating the induction of MET and the
overall kinetics of the process.
A network of conserved splicing changes in human and
mouse somatic cell reprogramming
Splicing patterns are known to change relatively rapidly
during mammalian evolution [40]. Nevertheless, given
the strong conservation of the splicing regulators, we
sought to identify genes and pathways in which
reprogramming-related splicing events occur in both hu-
man and mouse. To evaluate the significance of alterna-
tive splicing changes between reprogramming starting
and end points, we quantified the inclusion of annotated
alternatively spliced exons in terms of ‘percent spliced
in’ (PSI) values, a measure indicating the fraction of
transcripts that are consistent with a specific splicing
event among all transcripts generated from the corre-
sponding gene, across all samples. Principal compo-
nent analysis of PSI values of all quantified events
again revealed the expected clustering of the samples
(See figure on previous page.)
Fig. 3 ESRPs enhance reprogramming efficiency of TNG-MKOS-MEFs. (a) Number of Nanog-GFP+ colonies counted on day 15 of reprogramming
with/without overexpression of either Esrp1, Esrp2 or Renilla luciferase expression controls. Error bars show standard deviations and P values are
based on two-tailed paired t-tests (n = 3). See Additional file 16 for raw data. (b) Representative images of one entire culture dish per condition.
Images were taken by a Celigo Imaging cytometer. (c) Changes in CD44 and ICAM1 protein levels, measured by flow cytometry during the initial
stages of TNG-MKOS-MEF reprogramming (day 2 and day 5). TNG-MKOS-MEFs ectopically expressed either Renilla luciferase (left), Esrp1 (middle)
or Esrp2 (right). The gates define cells in different reprogramming stages as previously described [36]. The expected shift of cells along the
reprogramming time course is indicated in the schematic diagram on the right. Data from a representative experiment (of n = 3 experiments) are
shown. (d) Mean percentages of cells in each gate, with standard deviation computed from the three independent experiments. Gates are
labeled ICAM1+ / CD44+, ICAM- / CD44+, ICAM1- / CD44-, ICAM1+ / CD44- and correspond to the ones in (c), clockwise, starting from the top
right. An arrow next to the legend indicates the order in which sub-populations appear in a typical reprogramming experiment. See Additional
file 16 for raw data. (e and f) qRT-PCR measurements of epithelial and mesenchymal markers Cdh1 (e) and Cdh2 (f) at day 2 and 5 of the
reprogramming process. Samples were normalized to non-transduced samples for each day. GAPDH (glyceraldehyde-3-phosphate
dehydrogenase) was used as an internal control. Relative fold changes were calculated by the ΔΔCT method [89] . Error bars represent standard
deviations (n = 3). See Additional file 16 for raw data
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by cell type (Additional file 11: Figure S8A/B), al-
though the first two principal components explained
only 15-18% of the variance. Gene ontology analysis
of genes that underwent significant (P ≤ 0.05) splicing
changes showed relatively little overall conservation
across species (Additional file 11: Figure S8C).
We then extracted in each species the 500 splicing
events with the highest mean z-score across reprogram-
ming data (we have included the top 100 events in each
species for reference: Additional file 12: Figure S9 and
Additional file 13), identified the genes from which they
originated and then the orthologs in human and mouse.
We found 52 genes that are conserved targets of alterna-
tive splicing during reprogramming (Fig. 5a), which is
4-fold more than expected by chance (Fig. 5b; P value of
multi-set intersections = 2.47e-19). Thus, in spite of
relatively little conservation of splicing across species
[41], a substantial number of genes undergo splicing
changes during the reprogramming of both human and
mouse somatic cells. The majority of these genes are
connected through protein-protein interactions accord-
ing to the STRING analysis tool [42] (Fig. 5c), which is
again more than expected by chance (Fig. 5d; P values of
protein-protein interaction enrichment of 0.025 for hu-
man and 7.94 x 10-5 for mouse). The largest clusters of
conserved splicing targets correspond to epigenetic reg-
ulators, cell adhesion and cytoskeleton-associated mole-
cules, known modulators of cell fate (Fig. 5c). Focusing
on genes whose splicing is regulated by ESRP1/2 [15,
39], we found that only few undergo significant splicing
changes in both human and mouse (Fig. 5e). However,
those that do, i.e. NUMB (NUMB, endocytic adaptor
protein), ITGA6 (integrin subunit alpha 6) and FGFR1
(fibroblast growth factor receptor 1), are part of con-
served networks linked to pluripotency (Fig. 5c).
We have further conducted a reprogramming time
course experiment in the system described in the previous
sections, focusing on the early stages of the process (days
0-5 following doxycycline induction). A time point repre-
senting iPSCs (day 15) was also included. We have then
selected those of the top 100 differentially spliced events
identified for mouse (see above) that correspond to genes
from included in the described network of conserved spli-
cing changes (Fig. 5c) or predicted to be Esrp targets (Fig.
5e). Plotting the corresponding percent spliced in (PSI)
values for each day and condition (overexpression of
Esrp1, Esrp2 or Luciferase following retroviral transduc-
tion or no transduction) largely verified differential spli-
cing of these events between TNG-MKOS-MEFs and
iPSCs (Additional file 14: Figure S10A). However, al-
though the introduction of Esrp1 or Esrp2 cDNAs demon-
strably led to a considerable and specific increase in their
respective gene expression levels in the early stages of re-
programming (up to day 4; Additional file 14: Figure
S10B), we did not identify splicing patterns that were spe-
cific to their overexpression compared to control treat-
ments (Additional file 14: Figure S10A). We have also
specifically looked at the expression of Grhl1 isoforms, as
Grhl1 splicing has previously been reported to be affected
by Esrp1 during reprogramming (Cieply et al. 2016).
These isoforms were not included in the SUPPA index of
splicing events because the short Grhl1 isoform lacks mul-
tiple exons, and these complex splicing patterns are not
analyzed by the SUPPA software. While both Grhl1 iso-
forms are largely absent in TNG-MKOS-MEFs (Add-
itional file 14: Figure S10C; day 0) and only expressed at
low levels in iPSCs (day 15), their expression steadily in-
creases between days 1 and 5, reaching peak abundances
of approximately TPM = 5 (Grhl1-201) and TPM = 8
(Grhl1-202). However, while the relative abundance of the
isoforms (Additional file 14: Figure S10D; fraction of each
isoform by total gene expression) appears to be changing
between days 2, 5 and 15, a clear influence of elevated
Esrp1 or Esrp2 levels could not be observed (Additional
file 14: Figure S10D). One possible reason for the lack of a
consistent effect of Esrp overexpression on the splicing of
Grhl1 (Additional file 14: Figure S10D) and other genes
(Additional file 14: Figure S10A) might be the technical
limitations of accurate quantification of isoforms, particu-
larly of those with low abundances, leading to inaccurate
PSI estimations [43]. However, it may also be possible that
Esrp-induced changes in splicing patterns of the studied
events are saturated at endogenous levels or affect splicing
at later time points.
(See figure on previous page.)
Fig. 4 ESRPs regulate alternative splicing of CD44. (a) Schematic representation of the murine Cd44 gene model. Indicated are gene coordinates,
chromosome ruler, an arrow indicating the direction of transcription, exons, and transcript isoforms with Ensembl identifiers and symbols.
Colored boxes and expected PCR fragment sizes were added next to the transcript symbols to facilitate interpretation of (D). The mesenchymal
or “standard” (Cd44s) and the epithelial or “variable” (Cd44v) isoforms are highlighted. (b and c) Gene expression profile of the Cd44 gene in
human (b; study SRP049340) [28] and mouse (c; study SRP059670) [15] reprogramming time series (x axes). Expression levels (y axes) are given in
transcripts per million (TPM). Single- (red) and paired-end (blue) RNA-Seq libraries from study SRP059670 were analyzed separately. Dashed lines
indicate 95% confidence intervals. (d) Semi-quantitative RT-PCR of Cd44 isoforms at various time points (days 0, 2 and 5) of TNG-MKOS-MEF
reprogramming. Cells ectopically expressed either Esrp1 (E1), Esrp2 (E2), Renilla luciferase (Luc), or no transgene (not transduced, NT). M, 100 bp
DNA marker (NEB, #N3231S). The colored boxes represent the different transcript isoforms as defined in (a) Band intensities for the Cd44s isoform,
as quantified by AzureSpot (Azure Biosystems), are indicated below the gel photos (n = 2) as in (d). See Additional file 16 for raw quantification
data for all bands




Fig. 5 (See legend on next page.)
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Discussion
Stem cells have long held great promise for regenerative
medicine [44]. Thus, the demonstration that the gene
regulatory program of fully differentiated mammalian
cells can be overridden by temporarily expressing pluri-
potent stem cell-specific transcription factors to generate
induced pluripotent stem cells (iPSCs) [45, 46] had a
profound impact on basic and medical research [47].
iPSCs are used as experimental models to study a wide
range of diseases and to discover relevant drugs via
chemical library screenings [48]. They also serve as a
basis for grafting organoids and tissues [49–51]. A first
clinical trial involving patient-derived iPSCs is currently
ongoing [52] and several more will be launched within
the next decade [53]. Despite this tremendous progress,
our understanding of the process is still limited [54] and
the efficiency of transcription factor-driven reprogram-
ming remains in the percentage range [55]. Approaches
to increase it are in high demand.
Many different types of modulators have been already
identified. Very potent is vitamin C, which substantially
increases the efficiency of iPSC colony formation [56] by
promoting epigenetic remodeling through histone and
DNA demethylation [57, 58]. MicroRNAs of the
embryonically-expressed miR-302/367 cluster also in-
crease the efficiency of transcription factor-induced repro-
gramming, repressing targets that are involved in the cell
cycle, chromatin remodeling, vesicular transport and
epithelial-to-mesenchymal transition [59]. The related
miRNAs of the mouse-specific miR-290-295 cluster have
been reported to contribute to the stabilization of the
stem cell state by targeting epigenetic regulators [60–63].
Following discoveries that core transcriptional drivers of
reprogramming such as OCT4/POU5F1 and NANOG
(Nanog homeobox) are regulated by alternative splicing
[27, 64, 65], splicing factors have also been added to the
repertoire of modulators of the reprogramming process.
The general splicing factor SRSF2 has been linked to the
pluripotency as it affects the balance of MDB2
(methyl-CpG binding domain protein 2) isoforms, which
are part of a complex pluripotency circuit involving the
OCT4/POU5F1 transcription factor and the miR-302/367
miRNAs [27]. Conversely, SRSF11 acts as a roadblock for
reprogramming, its RNAi-mediated knockdown leading
to the rapid emergence of pluripotency-specific isoforms
[66]. MBNL1/2-dependent alternative splicing results in a
change in the sequence-specificity of the FOXP1 tran-
scription factor, with consequences for the efficiency of re-
programming [23, 67]. MBNL1 and MBNL2 are deeply
conserved pluripotency regulators, in functional antagon-
ism with CELF factors in the stem cells of planarian flat-
worms [17].
Many splicing factors that have so far been found to
modulate reprogramming efficiency act as reprogram-
ming roadblocks [12]. This may be because many studies
used small RNA-based screening to deplete individual
factors in early stages of reprogramming. However, as
we have found here, most splicing regulators increase in
expression during the reprogramming time course, and
one may expect them to rather promote reprogramming.
Indeed, this was demonstrated for Esrp1 [15, 16], the
splicing factor most strongly upregulated in iPSCs rela-
tive to parental cells (Fig. 2a).
While conventional human iPSCs and mouse iPSCs
represent ‘primed’ and ‘naive’ pluripotent states, respect-
ively, requiring distinct signaling pathways for their
self-renewal [68], the differences between these states
and the species-specific aspects of reprogramming are
not fully understood. Our analysis revealed that among
the core splicing regulators, ESRP2 has a different ex-
pression dynamics in mouse compared to human, mir-
roring the monotonic increase in expression of its
ESRP1 paralog in human reprogramming systems, but
undergoing only transient induction in mouse (Add-
itional file 7: Figure S4). Nevertheless, we found that just
as ESRP1, ESRP2 also accelerated the kinetics and in-
creased the efficiency of mouse cell reprogramming (Fig.
3a, b, c and d).
(See figure on previous page.)
Fig. 5 Consistent changes in alternative splicing. (a) Heatmap indicating absolute changes in ‘percent spliced in’ (ΔPSI) of splice variants (rows)
between reprogrammed and parental cells (columns). Gene symbols (human symbols shown) indicate the genes that harbor any of the 500 most
robust AS events, ranked by absolute mean z-scores across comparisons, in both human and mouse, with the shown absolute ΔPSI values
corresponding to the most robust event for a particular gene. Only events with a minimum combined expression of ≥2 TPM for all transcripts
involved in the event (median expression across all corresponding samples) were considered. Genes for which one-to-one pairwise orthologous
relationships and corresponding gene symbols were unavailable in Ensembl release 84 were disregarded. Column labels, dendrograms/clustering
and color coding of species as in Fig. 1d/e. (b) Overlap enrichment analysis of genes in (a) computed and represented as in Fig. 2b. (c)
Combined interaction network of proteins corresponding to the genes in panel (a), derived from STRING [42]. STRING analyses were carried out
individually for human and mouse, and the results were merged based on orthology relationships. The widths of connecting lines indicate
STRING confidence levels. Interactions reported for both organisms are shown in black, those annotated for human or mouse only are shown in
blue and red, respectively. Proteins with no interacting partners within the set were omitted. (d) STRING protein-protein interaction enrichment P
values. (e) As in (a), but only for reported ESRP targets [15, 39] and corresponding AS events. Here, events were not filtered based on expression.
Genes with symbols in blue, red or bold harbor the most robustly differentially spliced events (among top 100 or 500 AS events of a given
organism, as indicated by one or two correspondingly colored asterisks, respectively) in human, mouse, or both organisms, respectively
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Although splicing networks appear to evolve relatively
fast and splicing events are not strongly conserved in
evolution [40], we identified a core set of conserved spli-
cing targets that underwent significant changes across a
large number of reprogramming systems. This set is
likely incomplete, as the human and mouse transcrip-
tomes that we used for our analysis of isoform usage are
still not fully annotated. Furthermore, methods to quan-
tify isoform usage are still in development, and the
quantifications are not very accurate, particularly for low
abundance transcripts [43]. Nevertheless, we identified
conserved splicing targets in excess of what is expected
by chance. They encode proteins that promote remodel-
ling at the cellular and chromatin level, and are them-
selves subject to many regulatory influences. Cd44 is
one example: although the gene is strongly
down-regulated at the level of transcription in the early
stages of reprogramming, splicing of the produced tran-
scripts also changes, leading to isoforms that contain
epithelium-specific variable exons (CD44v) and are
expressed at low levels. Also heavily regulated are factors
that deposit or read DNA methylation marks, such as
DNTM3B (DNA methyltransferase 3 beta): apart from
undergoing alternative splicing, its expression is further
modulated by embryonically-expressed miR-290-295
miRNAs as well as MECP2 (methyl CpG binding protein
2), which is in turn regulated by the related family of
miR-302/367 miRNAs [63]. Isoform switching and
miRNA-dependent regulation has been reported for
other methyl-CpG binding domain proteins as well [27].
Multiple layers of regulation probably ensure that the
activity of these epigenetic regulators is precisely
controlled.
Conclusions
Through a comprehensive analysis of RNA sequencing
data sets obtained in studies of mouse, chimpanzee and
human somatic cell reprogramming, we uncovered an
extensive set of splicing factors that undergo conserved
changes in expression. In contrast to ESRP1, which
undergoes strong upregulation across all reprogramming
studies, the pattern of expression of its paralog, ESRP2,
differs between species. Nevertheless, both of these pro-
teins accelerate the kinetics and increase the reprogram-
ming efficiency of MEFs. The RNA sequencing data
further allowed us to reconstruct networks of splicing
targets that are conserved between species. They corres-
pond to proteins involved in subcellular structure and
traffic as well as in DNA modification. Although tran-
scription factors have been instrumental in changing cell
fates, the efficiency of somatic cell reprogramming re-
mains limited. A variety of molecules ranging from small
metabolites and miRNAs to splicing regulatory pro-
teins have been found to modulate the process. An
improved understanding of these factors’ functions
will enable a more controlled and efficient engineer-
ing of cell identity.
Methods
Gene and protein nomenclature
Gene symbols in this manuscript are italicized when refer-
ring to the gene itself, as well as derived transcripts and
cDNAs (e.g. the ESRP1 isoforms), but not when the corre-
sponding proteins are referenced (e.g. the ESRP1 protein).
Only when unambiguously referring to mouse genes,
cDNAs and mRNAs, symbols are specified in title case (e.g.
Esrp1). In all other cases, including in cases where general
statements are made about genes that are conserved across
primates and rodents, symbols are denoted in all capitals
(e.g. ESRP1 for the gene and ESRP1 for the protein). When
a gene is first referenced, the corresponding human name/
description is specified in parentheses right after the
symbol. In some cases, popular symbols or names are indi-
cated in addition to the (latest) official symbols/names.
RNA-Seq study search and selection
To obtain previously released data on iPSC reprogram-
ming and differentiation, the Gene Expression Omnibus
[69] was queried for relevant keywords ('iPSC' OR 'iPSCs'
OR 'iPS cells'; 'somatic' AND 'reprogramming'; 'induced'
AND 'reprogramming') on September 14th, 2016. More-
over, to be able to carry out the downstream analyses, we
required that the data were derived from organisms whose
genome sequence and corresponding gene annotations
are available at Ensembl [22, 70]. We inspected the corre-
sponding studies that had Illumina RNA-Seq-based se-
quencing data deposited at the NCBI Sequence Read
Archive [22] and retained only those studies that include
at least two replicates for each of iPSCs and the corre-
sponding tissues or cell lines of origin. The Illumina
RNA-Seq data of all included studies were downloaded
from the NCBI Sequence Read Archive and converted to
FASTQ format using the SRA Toolkit [71].
Genomes and other public resources
Genome sequences, gene annotations and sequences of ma-
ture mRNAs for human (GRCh38), mouse (GRCm38) and
chimpanzee (CHIMP2.1.4) were obtained from Ensembl
[70], release 84. On the genome level, unassembled regions,
haplotype and patch regions were disregarded. Genes anno-
tated on mitochondrial DNA and regions not assembled
into chromosomes were dropped from the gene annotations
and only genes of the following biotypes were kept: 'pro-
tein_coding', 'lincRNA', 'processed_transcript', 'antisense'.
Human and mouse transcripts were further filtered accord-
ing to their transcript support level (unavailable for chim-
panzee transcript annotations), with only transcripts of
support levels 1 through 3 being retained. This amounts to
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the minimal requirement that the transcript is supported by
a single non-suspect EST. For analyses of tissue-dependent
gene expression, we used the data (in transcripts per million;
TPM, in a each sample, log2-transformed) from The Hu-
man Protein Atlas (release 16) [31]. Log-transformed ex-
pression data for select genes in cancer and corresponding
normal tissue were obtained from The Cancer Genome
Atlas [72] through the FireBrowse ‘mRNASeq samples API’
[73]. Log2 fold changes for available tumor versus normal
tissue comparisons were computed based on the obtained
median expression values.
RNA-Seq analysis
Genome sequences, transcript sequences and gene anno-
tations were indexed using STAR v2.4.1c [74], kallisto
v0.42.3 [75] and SUPPA v2.1 [76] for read-to-genome
mapping, estimation of transcript abundance and quan-
tification of exon inclusion, respectively. Gene annota-
tions were provided during STAR index generation.
Cutadapt v1.8.3 [77] was used to remove poly(A) tail
fragments from reads of all sequencing libraries. Se-
quenced reads, in FASTQ format, were aligned to the
genome with the STAR aligner (Figure S1C/D for map-
ping rates). Transcript abundances were estimated with
kallisto, and based on these, the relative usage of tran-
script isoforms and alternative splicing events was quan-
tified with SUPPA. The means and standard deviations
of the fragment length distributions required by kallisto
for estimating transcript abundances from single-end se-
quencing libraries were set to 300±100 for single-end li-
braries obtained from the NCBI Sequence Read Archive.
The indexing of genome resources and processing of
RNA-Seq samples was performed with the help of the
Anduril workflow framework v1.2.23 [78]. Estimates of
gene expression were obtained by summing transcript
abundances and raw read counts (from kallisto; see data
sets 1-6 in [79]) for transcripts and reads corresponding
to individual genes. Before calculating principal compo-
nents, the gene-by-sample gene expression matrix (in
transcripts per million, TPM) for a given organism was
first log2-transformed and then zero-centered by col-
umns and rows.
Differential expression and splicing analyses
To compare gene expression between sample types of
interest (e.g. reprogrammed versus differentiated cells
from a given study), gene-level read count estimates [80]
for the corresponding samples (Additional file 2) were
used as input to the R/Bioconductor package edgeR
v3.12.0 [81] for differential gene expression analysis (see
data sets 7-12 in [79] for comprehensive summaries of log
fold changes and false discovery rates). Unless mentioned
otherwise, genes with a false discovery rate (Benjamini--
Hochberg method) of less than 0.05 were considered
differentially expressed. Gene set enrichment analyses
were performed with Ontologizer 2.1 (Build:
20160628-1269) [82] and calculation method “Term-For--
Term”. The ontology file (downloaded on 2016-12-24; in
OBO 1.2 format) was obtained from The Gene Ontology
Consortium [83]. Genes of a given organism associated
with each GO term were obtained from Ensembl BioMart
[84] Archive March 2016 version (corresponding to
Ensembl release 84) and converted to the GAF 2.0 format
by a custom script. ‘Percent spliced in’ (PSI) measures cal-
culated with SUPPA for each annotated alternative spli-
cing event (see data sets 13 and 14 in [79] for PSI values
in human and mouse, respectively) were further supplied
to SUPPA's diffSplice function [85] to identify differen-
tially spliced events in comparisons of interest (see data
sets 15-18 in [79] for comprehensive summaries of the
resulting ΔPSI and associated P values).
Orthologous genes & conservation analyses
Orthologous genes were obtained from Ensembl Bio-
Mart [84] (Archive March 2016 version, corresponding
to Ensembl release 84) and filtered for one-to-one rela-
tionships. Using the resulting table of corresponding
Ensembl identifiers for human, mouse and chimpanzee
(differential gene expression analysis only) orthologs, as
well as the Ensembl gene annotations (release 84, see
above) for individual species, Ensembl identifiers were
converted to human gene symbols. Only those genes
were kept whose Ensembl identifier could be unambigu-
ously matched to a unique gene symbol.
Reproducing the computational analyses
Generally, the indicated tools were ran according to
their primary use cases, thus requiring no or only very
little modification of default values. In other words: if at
all, default values Exhaustive information on how com-
putational analyses were performed and instructions for
replicating the analyses are available on GitHub [86].
Cell culture
Murine transgenic Nanog-GFP embryonic stem cells were
generated from the E14Tg2a mouse ES cell line in the
Smith lab as described previously (TNG-ESCs) [34] and
donated to the Kaji lab. TNG-MKOS-ESCs were derived
from TNG-ESCs by gene targeting the Sp3 locus with a
vector containing a 2A peptide-linked "Yamanaka factors"
(MKOS) gene cassette followed by ires-mOrange under a
tetracycline inducible promoter and a reverse tetracycline
transactivator (rtTA) under a constitutive CAG promoter,
as described previously [87]. Chimeric mouse embryos were
generated with TNG-MKOS-ESCs via morula aggregation.
TNG-MKOS-MEFs and wild-type MEFs were isolated at
E12.5 from chimeric and wild-type embryos, respectively,
as described previously [36]. NMuMG mouse mammary
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gland epithelial cells [88] and Phoenix-ECO cells were ob-
tained from the American Type Culture Collection (ATCC;
numbers CRL-1636 and CRL-3214, respectively).
Phoenix-ECO cells and TNG-MKOS-ESCs were cul-
tured in Glasgow Minimum Essential Medium (GMEM;
Sigma Aldrich, G5154), supplemented with 10% fetal bo-
vine serum (Invitrogen, 10270-106, Lot 41A1520K), 1X
non-essential amino acids (100X, Invitrogen, 11140-036),
1X Pen/Strep antibiotics, 1 mM sodium pyruvate (Invitro-
gen, 15140-122), 0.1 mM 2-mercaptoethanol (Life Tech-
nologies, 31350010), 2mM L-glutamine (Invitrogen,
25030-024) and 100,000U/ml of leukemia inhibitory factor
(LIF) (from Kaji lab, SCRM, University of Edinburgh).
This medium hereafter is referred to as normal medium.
Normal medium was supplemented with FGF-2 (5 ng/ml,
Preprotec, 100-18B) and heparin (1 μg/ml, Sigma Aldrich,
H3149) to culture wild-type and transgenic MEFs
(TNG-MKOS-MEFs). Reprogramming medium consisted
of normal medium with 1 μg/ml doxycycline (Sigma Al-
drich, D9891-1G), 10 μg/ml vitamin C (Sigma Aldrich,
1000731348) and 500 nM Alk5 inhibitor (A83-01, Tocris
Bioscience, 2939). NMuMG cells were cultured in Dulbec-
co's modified Eagle's medium (DMEM; Sigma Aldrich,
D5671) with high glucose and L-glutamine, supplemented
with 10% fetal bovine serum (Sigma-Aldrich, F7524).
Retroviral vectors and transductions
Retroviral vectors were constructed via an attR1/R2 Gate-
way cloning cassette (Invitrogen). Esrp1 and Esrp2 cDNAs
were PCR-amplified from NmuMG cells; Renilla luciferase
cDNA was PCR amplified from psiCHECK-2 (Promega AG,
C802A). See Additional file 5 for a list of the used primers.
cDNAs were cloned into the pENTR2B Gateway entry vec-
tor (Invitrogen, A10463) using EcoRI sites. Mutation-free in-
serts were gateway-cloned into a pMXs retro-vector [45]
using LR clonase (Invitrogen, 11791-020). Pseudo-retroviral
particles were produced by transfecting 10 μg of pMXs
retro-vectors expressing transgenes, separately for 48 hrs in
a 100 mm plate seeded with 2.2x106 Phoenix-ECO cells
(ATCC, CRL3214). Medium collected after 48 hrs of trans-
fection was filtered with 0.45 micron filter and mixed with
polybrene (TR-1003-G, Millipore) for transductions.
Reprogramming of transgenic mouse embryonic
fibroblasts
TNG-MKOS-MEFs were isolated from 12.5 dpc chimeric
embryos and contribution levels of transgenic cells were
measured by mOrange expression upon doxycycline ad-
ministration. For all reprogramming experiments con-
ducted in this study, 3% TNG-MKOS-MEFs were seeded
with 97% of wild-type MEFs in a gelatinized 6 well culture
plate. A total of 1x105 cells (3000 TNG-MKOS-MEFs and
97000 WT-MEFs) was seeded in each well of a 6 well
plate. Each well was transduced with 2 ml of retroviral
particles expressing Esrp1, Esrp2 and Renilla luciferase for
4 hours with polybrene (1ug/ml, Millipore, TR-10003-G).
After 4 hours medium was replaced with reprogramming
medium to induce reprogramming of TNG-MKOS-MEFs.
Expression of the transgenes was measured by qRT-PCR
after 4 days of transduction and induction of the repro-
gramming experiment (Figure S7A). Colony counting was
done after 15 days of reprogramming induction. The
number of colonies was determined by manual counting
and validated with the Celigo software.
Quantitative real-time PCR and RT-PCR
For qRT-PCRs assays, total RNA was extracted using
TRI reagent (Sigma Aldrich, T9424) and subjected to
DNase digestion with RQ1 DNase (Promega, M6101)
followed by phenol-chloroform (Sigma Aldrich, P3803)
purification. 1μg of total RNA was used for cDNA syn-
thesis using SuperScript III (Invitrogen, 18080-044) re-
verse transcriptase according to the manufacturer’s
protocol. 10 ng of cDNA per sample was added to
Power SYBR Green PCR Master Mix (Applied Biosys-
tems). Assays were performed in triplicates. See Add-
itional file 15 for a list of the used assays and primers.
Unless specified otherwise, GAPDH levels were used as
internal control, and the samples from non-transduced
controls or MKOS-ESCs [87] were used as external con-
trols. Relative fold changes were calculated according to
the ΔΔCT method [89]. RT-PCR products were stained
with RedSafe (iNtRON Biotechnology) and run on a
1.5% agarose gel. DNA was visualized at a wavelength of
290 nm. For the Cd44 RT-PCR assays, a Cd44 isoform
(ENSMUST00000005218) was PCR amplified (see Add-
itional file 15 for the primer sequences) and purified by
the QIAEX II gel extraction kit (Qiagen, 20021). The
DNA concentration was quantified by spectrophotom-
etry (NanoDrop). A series of 10-fold dilutions of this
DNA was used as a template for the generation of a
standard curve in which CT values were plotted against
the concentration of the template. The amounts of
cDNA to use in order to obtain equal amounts of Cd44
in each RT-PCR assay were calculated by linear regres-
sion from the standard curve. Pixel intensities of each
band of the resulting gel photos were quantified by the
AzureSpot analysis software (Azure Biosystems).
Flow cytometry, cell sorting and time course mRNA-
sequencing
Double staining of CD44 and ICAM1 was performed as
previously described [36, 88]. Briefly, TNG-MKOS-MEFs
infected with retroviral particles and treated with doxy-
cycline to induce reprogramming as described above,
were trypsinized, filtered through a cell strainer and
stained with fluorophore-conjugated antibodies of
ICAM1-Biotin (eBioscience, 13-0541-81, dilution-1:100),
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CD44-APC (eBioscience, 17-0441-81, dilution-1:100)
and Streptavidin-PE-Cyanine7 (eBioscience, 25-4317-82,
dilution-1:500) for 30 minutes, followed by two washing
steps with FACS buffer (2% FCS in PBS).
TNG-MKOS-MEFs were re-suspended in FACS buffer
and analyzed on an LSRFortessa Cell Analyzer (BD Bio-
sciences). Single-stained cells were used as controls. The
data was analyzed using FlowJo software (FlowJo LLC).
For the time course mRNA-sequencing libraries, 3 to
15% TNG-MEFs were seeded and transduced with retro-
viral particles expressing transgenes. After inducing repro-
gramming, around 3x105 mOrange positive cells were
sorted on FACSAria IIIu cell sorter (BD Biosciences) and
used the same for library preparation as described in [90].
Additional files
Additional file 1: Gene set enrichment analysis of SRP016568. The file
contains an XLSX spreadsheet summarizing the top 20 most enriched gene
ontology (GO) terms among the 6278 genes that were significantly more
highly expressed in iPSCs compared to foreskin fibroblasts in the study [21].
For comparison, the statistics for the same GO terms are also shown for the
gene set enrichment analysis done using all 11705 differentially expressed
genes. A total of 17249 genes were found to be expressed in the data sets
and were used as background. The first four columns, from left to right,
indicate the GO term identifier, name, ontology class/namespace, and the
total number of (human) genes that are associated with the term. The next
three columns indicate the number of genes associated with the term that
were found more highly expressed in iPSCs, the false discovery rate (FDR;
Benjamini-Hochberg) and the rank (by FDR) for the GO term enrichment.
The remaining three columns indicate the same parameters for all differen-
tially expressed genes. RNA-related GO terms have their names and identi-
fiers in bold and italics. Asterisks next to GO term identifiers indicate that
the term has the exact same set of genes associated with it as the preced-
ing one and is thus redundant. (XLSX 6 kb)
Additional file 2: RNA-Seq sample table. The file contains an XLSX
spreadsheet of the RNA-Seq data sets used in this study. For each sample
listed are, from left to right, the Sequence Read Archive (SRA) study and
run identifier, the organism and the cell type from which the sample was
derived, and a descriptive sample group name that was used to pool
samples for further analysis. (XLSX 14 kb)
Additional file 3: Figure S1. RNA-Seq library statistics. The following
parameters were evaluated for all analyzed reprogramming endpoint RNA-
Seq data sets and shown as bar-and-whisker plots, grouped by study: (A)
number of reads, (B) read length, (C) percent mapped reads, (D) percent
uniquely mapped reads. The Sequence Read Archive accessions for each
study are indicated on the y axes. Medians are indicated as thick black hori-
zontal lines. The lower and upper limits of boxes denote the first and third
quartile, respectively, while whiskers indicate the 5th (bottom) and 95th
(top) percentiles. Where applicable, outliers are indicated as circles. (PDF 17
kb)
Additional file 4: Table of comparisons for differential analyses. The file
contains an XLSX spreadsheet describing sample groups that were used for
differential and gene set enrichment analyses. Comparisons are always
between the end and start points of reprogramming (end point / start point
or, in log-space, end point - start point). The table lists, from left to right, the
Sequence Read Archive (SRA) study identifier, the organism from which the
samples were derived, the sample groups of reprogramming start and end
points, and a short name linking the comparisons to figures. (XLSX 5 kb)
Additional file 5: Figure S2. Distribution of gene expression changes.
(A) Absolute log2 fold changes in gene expression between all iPSC and
all fibroblast samples, irrespective of the species and study, are depicted
in a cumulative fraction plot. Only genes with exactly one ortholog in
each of human, mouse and chimpanzee were considered. The data in
red is from genes that are associated with GO term “RNA splicing”
(GO:0008380), while the data in blue is from remaining genes. The
statistic and P value of the Kolmogorov-Smirnov test calculated for the
data sets is indicated. (B) As in (A), but log2 fold changes are depicted in
density plots and statistics (Student’s t-test; t and corresponding P value)
for the difference of the means are indicated. (C and D) as in (A and B),
respectively, but data for genes associated (red) or not associated (blue)
with GO term “RNA processing” (GO:0006396) is plotted. (E and F) as in (A
and B), respectively, but data for genes associated (red) or not associated
(blue) with GO term “gene expression” (GO:0010467) is plotted. (G and H)
as in (A and B), respectively, but data for genes associated (red) or not
associated (blue) with GO term “spliceosomal complex” (GO:0005681) is
plotted. (I and J) as in (A and B), respectively, but data for genes
associated (red) or not associated (blue) with GO term “ribosome”
(GO:0005840) is plotted. (PDF 521 kb)
Additional file 6: Figure S3. Human reprogramming time course. The
expression profile of splicing factors from Fig. 2a (y-axes, in TPM) shown as a
function of time (in days; x axes), from the hiF-T reprogramming experiment
(SRP049340) [28]. Dashed lines indicate 95% confidence intervals. (PDF 19 kb)
Additional file 7: Figure S4. Mouse reprogramming time course. As in
Figure S3 but data is from mouse embryonic fibroblast reprogramming
(study SRP059670) [15]. For each time point, data from single- (red) and
paired-end (blue) RNA-Seq were available. (PDF 23 kb)
Additional file 8: Figure S5. Changes in splicing factor expression in
cancers. Fold changes in expression of individual factors (from Fig. 2a) between
cancers and corresponding healthy tissues are depicted. Data and tumor/
cancer classifications are from The Cancer Genome Atlas (TCGA). Organisms
and dendrograms as in Fig. 1d/e, splicing factor bins (orange, white, blue or
mixed color boxes next to the gene symbols) as in Fig. 2a. (PDF 25 kb)
Additional file 9: Figure S6. RNA processing factors with consistent
changes in gene expression. (A and B) As in Fig. 2a and b, respectively,
but for genes (y axis; human gene symbol used) associated with GO term
“RNA processing” (GO:0006396) and its children. Symbols of genes not
associated with GO term “RNA splicing” (GO:0008380), which is a
descendent of “RNA processing”, are highlighted (maroon). In contrast to
Fig. 2a, splicing factors previously implicated in somatic cell
reprogramming are only included if they exceeded the expression and
fold change cut-offs. (PDF 82 kb)
Additional file 10: Figure S7. In vitro characterization of iPSCs. (A)
qRT-PCR measurements of Esrp1/2 expression 4 days after retroviral
transduction of TNG-MKOS7-MEFs, relative to non-transduced TNG-MKOS-
MEFs. Error bars indicate standard deviations (n = 3). See Additional file
16 for raw data. (B) Genomic PCR of iPSC clones demonstrating the
integration of the indicated transgenes. M, 100 bp DNA marker (Invitrogen,
15628-019). (C) Relative expression of pluripotency markers in iPSC clones
derived from TNG-MKOS-MEFs expressing the indicated transgenes compared
to embryonic stem cells, as analyzed by qRT-PCR. ESC, embryonic stem cells
(MKOS cassette) [87]. See Fig. 4d for abbreviations and Additional file 16 for
raw data. (D) Germ layer specific marker expression analyzed by qRT-PCR after
the induction of spontaneous differentiation in embryonic stem cells (ESC)
and iPSC clones expressing the indicated transgenes. See Fig. 4d for
abbreviations and Additional file 16 for raw data. (E) Images of embryoid
bodies derived from iPSC clones carrying the indicated transgenes. Scale bar
100 μm. (F) Directed differentiation of iPSCs was performed as described
previously [94]. Representative images of neurons derived from iPSC clones
carrying the indicated transgenes. Green represents β-III tubulin (eBioscience,
14-4510-80) and blue represents nuclei stained with Hoechst dye. Scale bar: 10
μm. (PDF 537 kb)
Additional file 11: Figure S8. Analysis of alternative splicing. (A and B)
As in Fig. 1a and b, but instead of gene expression values, the ‘percent
spliced in’ (PSI) values calculated by SUPPA [76] for all indexed human (A)
and mouse (B) alternative splicing events and then analyzed by principal
component analysis. (C) Similar to Fig. 1d, but gene set enrichment
analyses were performed for differentially spliced genes versus all genes
with annotated isoforms. Log10 false discovery rates (FDR) of all GO
terms (rows) that were found enriched (FDR < 0.1) in at least half of
human (blue boxes above heatmap) or mouse (red boxes) comparisons
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(columns) are plotted. Highly significant values were capped at log10
FDR = -5, for clarity. GO term categories are indicated as an extra column
to the right of the heatmap: BP, biological process; CC, cellular
compartment; MF, molecular function. (PDF 43 kb)
Additional file 12: Figure S9. Splicing events in human and mouse
reprogramming. The heatmaps depict ‘percent spliced in’ (PSI) values
across the indicated comparisons (column labels) for the top 100
alternative splicing (AS) events (row labels), ranked by absolute mean z-
scores across comparisons, in human (A) and mouse (B). Row labels rep-
resent shorthand event identifiers derived from gene symbols or, if un-
available, Ensembl gene identifiers. See Additional file 3 for the
corresponding SUPPA event identifiers. AS event classes are indicated by
colored boxes with the following abbreviations: A3, alternative 3’ splice
site; A5, alternative 5’ splice site; AF, alternative first exons; AL, alternative
last exon; MX, mutually exclusive exons; RI, retained intron; SE, skipping
exon. Filtering of events by expression as in Fig. 5a. Dendrograms/cluster-
ing as in Fig. 1d/e. (PDF 62 kb)
Additional file 13: Top ranked alternative splicing events for human and
mouse reprogramming. The file contains an XLSX spreadsheet with
information on the 100 top ranked alternative splicing events derived from
Ensembl gene annotations (release 84) [70], as identified in a set of
endpoint-to-endpoint comparisons of human (first tab) or mouse (second
tab) somatic cell reprogramming experiments. Splice sites were ranked ac-
cording to mean z-scores. The unique shorthand event identifiers (Figure
S9), as well as the corresponding SUPPA event identifiers, Ensembl gene
identifiers, gene symbols and SUPPA event types are indicated. (XLSX 17 kb)
Additional file 14: Figure S10. Impact of Esrp1/2 overexpression on
selected splicing events. TNG-MKOS-MEFs transduced with retroviruses
harboring expression cassettes for either Esrp1 (green), Esrp2 (purple) or
Luciferase (red), or not transduced (blue) were treated with doxycycline
to induce reprogramming. RNA-Seq libraries (n = 1) were generated from
samples taken at day 0 through 5 and day 15 (representing fully repro-
grammed iPSCs). (A) Percent spliced in (PSI) values are plotted for each
day for those of the mouse events in Additional file 3 that correspond to
genes that have been associated with the network of splicing changes in
Fig. 5c or have previously been identified as Esrp1/2 targets [15, 39]. (B)
Total gene expression of Esrp1 (top) and Esrp2 (bottom) along the repro-
gramming time course. (C and D) The fractions of total Grhl1 gene ex-
pression (C) and abundances (D) of the Grhl1 isoforms 201 and 202 are
indicated for each time point. (PDF 53 kb)
Additional file 15: Table of primers and PCR assays. The XLSX
spreadsheet file contains a list of all primers used for the cloning of
transgenes into retroviral vectors, qRT-PCR assays for pluripotency, differenti-
ation, epithelial and mesenchymal markers, genomic PCR reactions for trans-
genes derived from iPSC clones, and Cd44 RT-PCR reactions. (XLSX 7 kb)
Additional file 16: Raw data. Raw data values for relevant experiments
are summarized in an XLSX spreadsheet. Data from each figure panel is
presented in a single sheet. Labels correspond to those used in the
figures. (XLSX 56 kb)
Abbreviations
(c)iPSC: (chemically) induced pluripotent stem cells; (Δ)PSI: (delta) percent
spliced in; APC: Adipose progenitor cells; EMT: Epithelial-mesenchymal
transition; FB: Fibroblasts; GO: Gene ontology; hiF(-T): Human inducible
fibroblast-like cells (constitutively express human Telomerase);
HPC: Hematopoietic progenitor cells; LB: Lymphoblastoid cells; MEF: Mouse
embryonic fibroblasts; MET: Mesenchymal-epithelial transition;
MKOS: Expression cassette harboring cDNAs for Myc, Klf4, Oct4 and Sox2;
SSC: Spermatogonial stem cells; TNG-MKOS-MEF: Transgenic MEFs with
MKOS cassette; TPM: Transcripts per million
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